PharmaKure

PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Diseases

New collaboration will enhance ability to identify those more at risk of developing brain diseases to enable earlier interventions 29 February 2024 -- Manchester, UK -- PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease (AD) and other neurodegenerative diseases, today announces a new epigenetics collaboration with Sheffield Hallam University, UK. This...

PharmaKure announces study success for novel blood test to identify biomarkers in patients with Alzheimer’s Disease

Study confirms ALZmetrix whole blood test can detect people at high risk of developing full Alzheimer’s Disease 17 October 2023 -- Manchester, UK -- PharmaKure, a pharmaceutical company spun out from the University of Manchester, announces successful study results for a novel whole blood test for quantifying Alzheimer’s Disease biomarkers. PharmaKure’s proprietary ALZmetrix blood test...
Alderley Park Congleton Road Nether Alderley Open Access Lab 19S6 Macclesfield SK10 4TG